Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)
|ClinicalTrials.gov Identifier: NCT00506545|
Recruitment Status : Completed
First Posted : July 25, 2007
Last Update Posted : November 27, 2013
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
This is a randomized, double-blind, placebo-controlled, crossover, single center study of SCH 619734 in subjects with chronic cough from an unknown cause. Subjects will be randomized to receive SCH 619734 or placebo for 7 days with 7 days' follow-up. After a 6 week washout period, subjects will be crossed over to the other treatment. The primary objective is to evaluate the effectiveness of SCH 619734 in reducing cough reflex sensitivity as determined by a challenge with capsaicin, an agent that induces cough.
|Condition or disease||Intervention/treatment||Phase|
|Cough||Drug: SCH 619734 Drug: Placebo Dose 1||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||35 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Idiopathic Cough|
|Study Start Date :||January 2007|
|Actual Primary Completion Date :||October 2007|
|Actual Study Completion Date :||October 2007|
|Experimental: SCH 619734||
Drug: SCH 619734
SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
Other Name: Rolapitant
|Placebo Comparator: Placebo||
Drug: Placebo Dose 1
Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
Primary Outcome Measures :
- Change from baseline in cough reflex sensitivity as assessed by log10 C5 resulting from a capsaicin challenge. A capsaicin challenge will be performed on the first day of each treatment week (before dosing) and on the last day of each treatment week. [ Time Frame: At Days 7 and 63. ]
Secondary Outcome Measures :
- Change from baseline in hourly cough rate over 24 hours (using an automated cough counter). Baseline will be measured as the total number of coughs on Days -1 and 56 and compared with the total number of coughs on the last day of each treatment week. [ Time Frame: At Days 7 and 63. ]
No Contacts or Locations Provided